ScaleReady announces multiple G-Rex® Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of $665,000 in G-Rex Grant funding to three investigators at the University of Minnesota's Center for Genome Engineering [1] Funding Details - Dr. Branden Moriarity received a $300,000 G-Rex Grant for a novel hyper-functional CAR NK cell therapy targeting advanced epithelial ovarian cancer in a Phase 1 clinical trial [2] - Dr. Beau Webber was awarded $240,000 for preclinical development of a novel TIL therapy for various solid tumors [3] - Dr. Joseph Skeate received $125,000 to support process development for TPP1 expressing T cells therapy for Batten Disease [4] Industry Impact - The G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development and manufacturing [7] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [10] Additional Initiatives - ScaleReady introduced a free program called LEAN Cell & Gene™ to help CGT entities improve efficiency and quality in manufacturing [8]